Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline - Top_Thought_Leaders - MDSpire

Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline

New innovations targeting dry eye disease (DED) are in the pipeline to enable us to tailor our treatments to the specific underlying causes of DED.

  • By

  • SHANE R. KANNARR, OD

  • Christoper J. Jacquinot, OD

  • Ryan A. Cedeno, OD

  • July 1, 2025

  • 1 min

Share

Top Thought Leaders in Optometry

Brief introduction explaining scope and methodology.

Original Source(s)

Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline

  • by SHANE R. KANNARR, OD, Christoper J. Jacquinot, OD, Ryan A. Cedeno, OD

  • July 1, 2025

Related Content

Ocular Surface Optimization: The Best First Step in Modern Cataract Surgery

Why a healthy preoperative ocular surface is no longer optional

Asymptomatic Meibomian Gland Characteristics 

Silent gland failure: what do asymptomatic adults reveal about subclinical MGD?

  • January 14, 2026

  • 3 min
AAO Opens Call for Course Proposals for Academy 2026 Anaheim

The American Academy of Optometry (AAO) has opened its call for course proposals for the educational program at Academy 2026 Anaheim, inviting optometrists and educators to submit lectures, workshops, and interactive sessions for consideration.